Integrating network pharmacology and experimental validation to decipher the mechanism of the Chinese herbal prescription modified Shen-Yan-Fang-Shuai formula in treating diabetic nephropathy

References

• Barutta F, Bruno G, Grimaldi S, Gruden G. 2015. Inflammation in diabetic nephropathy: moving toward clinical biomarkers and targets for treatment. Endocrine. 48(3):730–742. doi: 10.1007/s12020-014-0437-1.
   PubMed Web of Science ®Google Scholar
• Chen P, Yuan Y, Zhang T, Xu B, Gao Q, Guan T. 2018. Pentosan polysulfate ameliorates apoptosis and inflammation by suppressing activation of the p38 MAPK pathway in high glucose-treated HK-2 cells. Int J Mol Med. 41(2):908–914. doi: 10.3892/ijmm.2017.3290.
   PubMed Web of Science ®Google Scholar
• Cheng HT, Xu X, Lim PS, Hung KY. 2021. Worldwide epidemiology of diabetes-related end-stage renal disease, 2000-2015. Diabetes Care. 44(1):89–97. doi: 10.2337/dc20-1913.
   PubMed Web of Science ®Google Scholar
• Cheng X, Gao W, Dang Y, Liu X, Li Y, Peng X, Ye X. 2013. Both ERK/MAPK and TGF-Beta/Smad signaling pathways play a role in the kidney fibrosis of diabetic mice accelerated by blood glucose fluctuation. J Diabetes Res. 2013:463740. doi: 10.1155/2013/463740.
   PubMed Web of Science ®Google Scholar
• Doshi SM, Friedman AN. 2017. Diagnosis and management of type 2 diabetic kidney disease. Clin J Am Soc Nephrol. 12(8):1366–1373. doi: 10.2215/CJN.11111016.
   PubMed Web of Science ®Google Scholar
• Forbes JM, Cooper ME. 2013. Mechanisms of diabetic complications. Physiol Rev. 93(1):137–188. doi: 10.1152/physrev.00045.2011.
   PubMed Web of Science ®Google Scholar
• Geng XQ, Ma A, He JZ, Wang L, Jia YL, Shao GY, Li M, Zhou H, Lin SQ, Ran JH, et al. 2020. Ganoderic acid hinders renal fibrosis via suppressing the TGF-β/Smad and MAPK signaling pathways. Acta Pharmacol Sin. 41(5):670–677. doi: 10.1038/s41401-019-0324-7.
   PubMed Web of Science ®Google Scholar
• Gilbert RE, Cooper ME. 1999. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int. 56(5):1627–1637. doi: 10.1046/j.1523-1755.1999.00721.x.
   PubMed Web of Science ®Google Scholar
• Gilbert RE. 2017. Proximal tubulopathy: prime mover and key therapeutic target in diabetic kidney disease. Diabetes. 66(4):791–800. doi: 10.2337/db16-0796.
   PubMed Web of Science ®Google Scholar
• Gratton JP, Morales-Ruiz M, Kureishi Y, Fulton D, Walsh K, Sessa WC. 2001. Akt down-regulation of p38 signaling provides a novel mechanism of vascular endothelial growth factor-mediated cytoprotection in endothelial cells. J Biol Chem. 276(32):30359–30365. doi: 10.1074/jbc.M009698200.
   PubMed Web of Science ®Google Scholar
• Guo JC, Pan HC, Yeh BY, Lu YC, Chen JL, Yang CW, Chen YC, Lin YH, Chen HY. 2021. Associations between using Chinese herbal medicine and long-term outcome among pre-dialysis diabetic nephropathy patients: a retrospective population-based cohort study. Front Pharmacol. 12(12):616522. doi: 10.3389/fphar.2021.616522.
   PubMedGoogle Scholar
• He S, Hu Q, Xu X, Niu Y, Chen Y, Lu Y, Su Q, Qin L. 2020. Advanced glycation end products enhance M1 macrophage polarization by activating the MAPK pathway. Biochem Biophys Res Commun. 525(2):334–340. doi: 10.1016/j.bbrc.2020.02.053.
   PubMed Web of Science ®Google Scholar
• Heinrich M, Appendino G, Efferth T, Fürst R, Izzo AA, Kayser O, Pezzuto JM, Viljoen A. 2020. Best practice in research - overcoming common challenges in phytopharmacological research. J Ethnopharmacol. 246:112230. doi: 10.1016/j.jep.2019.112230.
   PubMed Web of Science ®Google Scholar
• Honma S, Shinohara M, Takahashi N, Nakamura K, Hamano S, Mitazaki S, Abe S, Yoshida M. 2014. Effect of cyclooxygenase (COX)-2 inhibition on mouse renal interstitial fibrosis. Eur J Pharmacol. 740:578–583. doi: 10.1016/j.ejphar.2014.06.027.
   PubMed Web of Science ®Google Scholar
• Hu C, Sun L, Xiao L, Han Y, Fu X, Xiong X, Xu X, Liu Y, Yang S, Liu F, et al. 2015. Insights into the mechanisms involved in the expression and regulation of extracellular matrix proteins in diabetic nephropathy. Curr Med Chem. 22(24):2858–2870. doi: 10.2174/0929867322666150625095407.
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. 2021. IDF Diabetes Atlas, 10th edn. Brussels, Belgium. https://www.diabetesatlas.org
   Google Scholar
• Lakshmanan AP, Thandavarayan RA, Watanabe K, Sari FR, Meilei H, Giridharan VV, Sukumaran V, Soetikno V, Arumugam S, Suzuki K, et al. 2012. Modulation of AT-1R/MAPK cascade by an olmesartan treatment attenuates diabetic nephropathy in streptozotocin-induced diabetic mice. Mol Cell Endocrinol. 348(1):104–111. doi: 10.1016/j.mce.2011.07.041.
   PubMed Web of Science ®Google Scholar
• Li J, Jin S, Barati MT, Rane S, Lin Q, Tan Y, Cai L, Rane MJ. 2021. ERK and p38 MAPK inhibition controls NF-E2 degradation and profibrotic signaling in renal proximal tubule cells. Life Sci. 287:120092. doi: 10.1016/j.lfs.2021.120092.
   PubMed Web of Science ®Google Scholar
• Lim A. 2014. Diabetic nephropathy – complications and treatment. Int J Nephrol Renovasc Dis. 7:361–381. doi: 10.2147/IJNRD.S40172.
   PubMedGoogle Scholar
• Lin YK, Gao B, Liu L, Ang L, Mizokami-Stout K, Pop-Busui R, Zhang L. 2021. The prevalence of diabetic microvascular complications in China and the USA. Curr Diab Rep. 21(6):16. doi: 10.1007/s11892-021-01387-3.
   PubMed Web of Science ®Google Scholar
• Lohr J, Mazurchuk RJ, Acara MA, Nickerson PA, Fiel RJ. 1991. Magnetic resonance imaging (MRI) and pathophysiology of the rat kidney in streptozotocin-induced diabetes. Magn Reson Imaging. 9(1):93–100. doi: 10.1016/0730-725x(91)90102-r.
   PubMed Web of Science ®Google Scholar
• Lu Z, Zhong Y, Liu W, Xiang L, Deng Y. 2019. The efficacy and mechanism of Chinese herbal medicine on diabetic kidney disease. J Diabetes Res. 2019:2697672. doi: 10.1155/2019/2697672.
   PubMed Web of Science ®Google Scholar
• Lv J, Wang Z, Wang Y, Sun W, Zhou J, Wang M, Liu WJ, Wang Y. 2017. renoprotective effect of the Shen-Yan-Fang-Shuai formula by inhibiting TNF-α/NF-κB signaling pathway in diabetic rats. J Diabetes Res. 2017:4319057. doi: 10.1155/2017/4319057.
   PubMed Web of Science ®Google Scholar
• Ma LL, Wang MZ, Liu YN, Yang HT, Wang YX. 2020. Exploratory study of nephritis prevention solution to delay the timing of dialysis in non-dialysis patients with chronic kidney disease stage 5. Chinese J Trad Chinese Med. 35:2120–2123. Chinese.
   Google Scholar
• Maezawa Y, Takemoto M, Yokote K. 2015. Cell biology of diabetic nephropathy: roles of endothelial cells, tubulointerstitial cells and podocytes. J Diabetes Investig. 6(1):3–15. doi: 10.1111/jdi.12255.
   PubMed Web of Science ®Google Scholar
• Malik S, Suchal K, Khan SI, Bhatia J, Kishore K, Dinda AK, Arya DS. 2017. Apigenin ameliorates streptozotocin-induced diabetic nephropathy in rats via MAPK-NF-κB-TNF-α and TGF-β1-MAPK-fibronectin pathways. Am J Physiol Renal Physiol. 313(2):F414–F422. doi: 10.1152/ajprenal.00393.2016.
   PubMed Web of Science ®Google Scholar
• Najafian B, Alpers CE, Fogo AB. 2011. Pathology of human diabetic nephropathy. Contrib Nephrol. 170:36–47.
   PubMed Web of Science ®Google Scholar
• Navarro JF, Milena FJ, Mora C, León C, García J. 2006. Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration. Am J Nephrol. 26(6):562–570. doi: 10.1159/000098004.
   PubMed Web of Science ®Google Scholar
• Ouyang Y, Rong Y, Wang Y, Guo Y, Shan L, Yu X, Li L, Si J, Li X, Ma K. 2021. A systematic study of the mechanism of acacetin against sepsis based on network pharmacology and experimental validation. Front Pharmacol. 12:683645. doi: 10.3389/fphar.2021.683645.
   PubMed Web of Science ®Google Scholar
• Peti W, Page R. 2013. Molecular basis of MAP kinase regulation. Protein Sci. 22(12):1698–1710. doi: 10.1002/pro.2374.
   PubMed Web of Science ®Google Scholar
• Qi C, Mao X, Zhang Z, Wu H. 2017. Classification and differential diagnosis of diabetic nephropathy. J Diabetes Res. 2017:8637138. doi: 10.1155/2017/8637138.
   PubMed Web of Science ®Google Scholar
• Ranganathan P, Jayakumar C, Ramesh G. 2013. Proximal tubule-specific overexpression of netrin-1 suppresses acute kidney injury-induced interstitial fibrosis and glomerulosclerosis through suppression of IL-6/STAT3 signaling. Am J Physiol Renal Physiol. 304(8):F1054–65. doi: 10.1152/ajprenal.00650.2012.
   PubMed Web of Science ®Google Scholar
• Roy A, Maiti A, Sinha A, Baidya A, Basu AK, Sarkar D, Sanyal D, Biswas D, Maisnam I, Pandit K, et al. 2020. Kidney disease in type 2 diabetes mellitus and benefits of sodium-glucose cotransporter 2 inhibitors: a consensus statement. Diabetes Ther. 11(12):2791–2827. doi: 10.1007/s13300-020-00921-y.
   PubMed Web of Science ®Google Scholar
• Ru J, Li P, Wang J, Zhou W, Li B, Huang C, Li P, Guo Z, Tao W, Yang Y, et al. 2014. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform. 6:13–18. doi: 10.1186/1758-2946-6-13.
   PubMed Web of Science ®Google Scholar
• Samsu N. 2021. Diabetic nephropathy: challenges in pathogenesis, diagnosis, and treatment. Biomed Res Int. 2021:1497449. doi: 10.1155/2021/1497449.
   PubMed Web of Science ®Google Scholar
• Selby NM, Taal MW. 2020. An updated overview of diabetic nephropathy: diagnosis, prognosis, treatment goals and latest guidelines. Diabetes Obes Metab. 22 (Suppl 1):3–15. doi: 10.1111/dom.14007.
   PubMed Web of Science ®Google Scholar
• Sharma D, Bhattacharya P, Kalia K, Tiwari V. 2017. Diabetic nephropathy: new insights into established therapeutic paradigms and novel molecular targets. Diabetes Res Clin Pract. 128:91–108. doi: 10.1016/j.diabres.2017.04.010.
   PubMed Web of Science ®Google Scholar
• Sharma D, Gondaliya P, Tiwari V, Kalia K. 2019. Kaempferol attenuates diabetic nephropathy by inhibiting RhoA/Rho-kinase mediated inflammatory signalling. Biomed Pharmacother. 109:1610–1619. doi: 10.1016/j.biopha.2018.10.195.
   PubMed Web of Science ®Google Scholar
• Sharma D, Verma S, Vaidya S, Kalia K, Tiwari V. 2018. Recent updates on GLP-1 agonists: current advancements & challenges. Biomed Pharmacother. 108:952–962. doi: 10.1016/j.biopha.2018.08.088.
   PubMed Web of Science ®Google Scholar
• Wang J, Xiang H, Lu Y, Wu T, Ji G. 2021. New progress in drugs treatment of diabetic kidney disease. Biomed Pharmacother. 141:111918. doi: 10.1016/j.biopha.2021.111918.
   PubMed Web of Science ®Google Scholar
• Wang W, Sun W, Cheng Y, Xu Z, Cai L. 2019. Role of sirtuin-1 in diabetic nephropathy. J Mol Med (Berl). 97(3):291–309. doi: 10.1007/s00109-019-01743-7.
   PubMed Web of Science ®Google Scholar
• Wang X, Hu Y, Zhou X, Li S. 2022. Editorial: network pharmacology and traditional medicine: setting the new standards by combining In silico and experimental work. Front Pharmacol. 13(13):1002537. doi: 10.3389/fphar.2022.1002537.
   PubMedGoogle Scholar
• Wang X, Wang ZY, Zheng JH, Li S. 2021. TCM network pharmacology: a new trend towards combining computational, experimental and clinical approaches. Chin J Nat Med. 19(1):1–11. doi: 10.1016/S1875-5364(21)60001-8.
   PubMed Web of Science ®Google Scholar
• Warren AM, Knudsen ST, Cooper ME. 2019. Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies. Expert Opin Ther Targets. 23(7):579–591. doi: 10.1080/14728222.2019.1624721.
   PubMed Web of Science ®Google Scholar
• Wei X, Hou W, Liang J, Fang P, Dou B, Wang Z, Sai J, Xu T, Ma C, Zhang Q, et al. 2021. Network pharmacology-based analysis on the potential biological mechanisms of sinisan against non-alcoholic fatty liver disease. Front Pharmacol. 12:693701. doi: 10.3389/fphar.2021.693701.
   PubMed Web of Science ®Google Scholar
• Wu Y, Zhang F, Yang K, Fang S, Bu D, Li H, Sun L, Hu H, Gao K, Wang W, et al. 2019. SymMap: an integrative database of traditional Chinese medicine enhanced by symptom mapping. Nucleic Acids Res. 47(D1):D1110–D1117. doi: 10.1093/nar/gky1021.
   PubMed Web of Science ®Google Scholar
• Yao JQ, Gao YX, Wang YX, Teng FB. 2019. Experimental case of diabetic nephropathy treated by staging with the ‘micro-Zhengjia’ theory. Chinese J Clinicians. 47:121–123. Chinese.
   Google Scholar
• Yue J, López JM. 2020. Understanding MAPK signaling pathways in apoptosis. Int J Mol Sci. 21:2346. doi: 10.3390/ijms21072346.
   PubMed Web of Science ®Google Scholar
• Zhang YH, Zhang YQ, Guo CC, Wang LK, Cui YJ, Dong JJ, Liao L. 2020. Prostaglandin E1 attenuates high glucose-induced apoptosis in proximal renal tubular cells by inhibiting the JNK/Bim pathway. Acta Pharmacol Sin. 41(4):561–571. doi: 10.1038/s41401-019-0314-9.
   PubMed Web of Science ®Google Scholar